US2023355514A1PendingUtilityA1
Pharmaceutical formulations
Est. expiryFeb 7, 2034(~7.6 yrs left)· nominal 20-yr term from priority
A61K 9/0065A61K 9/2018A61K 9/2027A61K 9/2031A61K 9/2054A61K 31/133A61K 31/135A61K 31/137A61K 31/4439A61K 31/19A61K 31/437A61K 31/4745A61K 31/522A61K 9/2013A61K 9/284A61K 31/00A61K 31/4196A61K 31/4375
82
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
Claims
exact text as granted — not AI-modified1 . An extended-release pharmaceutical formulation comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2 and about 18% of an active ingredient that is tetrabenazine; between about 70% and about 96% of one or more diluents selected from the group consisting of mannitol powder, spray dried mannitol, microcrystalline cellulose, lactose, dicalcium phosphate, tricalcium phosphate, starch, pregelatinized starch, compressible sugars, silicified microcrystalline cellulose, and calcium carbonate; between about 1% and about 10% of a water-soluble binder selected from the group consisting of polyvinylpyrrolidone, hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), corn starch, pregelatinized starch, gelatin, and sugar; and between about 0.5 and about 2% of a surfactant selected from the group consisting of polysorbate, sodium lauryl sulfate, and docusate sodium.
Join the waitlist — get patent alerts
Track US2023355514A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.